Last updated: August 1, 2026
AstraZeneca is one of the world’s largest biopharmaceutical companies, with leadership in oncology, cardiovascular-renal-metabolic disease, respiratory medicine, immunology, and rare disease. Its 2024 total revenue was approximately $54.1 billion, including product sales and alliance revenue, according to company reporting. Oncology represented the largest business area, supported by Tagrisso, Imfinzi, Imjudo, Enhertu economics, Calquence, Lynparza, and other targeted therapies (AstraZeneca, 2025a).
The company’s competitive position rests on four factors: a large oncology portfolio, significant biologics exposure, rare-disease assets acquired through Alexion, and a late-stage pipeline designed to replace revenue lost to patent expiry. Its principal risks are concentration in a small group of blockbuster products, patent challenges to mature medicines, pricing pressure in the United States, biosimilar competition, and execution risk from large-scale business-development transactions.
What is AstraZeneca’s market position in the pharmaceutical industry?
AstraZeneca ranks among the largest global innovative pharmaceutical companies by revenue and has a stronger specialty-medicine profile than many diversified competitors.
| Metric |
AstraZeneca position |
| 2024 total revenue |
Approximately $54.1 billion |
| Core therapeutic areas |
Oncology; cardiovascular, renal and metabolic disease; respiratory and immunology; rare disease |
| Largest business area |
Oncology |
| Key growth assets |
Tagrisso, Farxiga, Imfinzi, Calquence, Ultomiris, Fasenra, Enhertu |
| Principal acquired platform |
Alexion rare disease portfolio |
| Geographic exposure |
United States, Europe, China, Japan and emerging markets |
| Main competitive threats |
Merck, Bristol Myers Squibb, Johnson & Johnson, Roche, Novartis, Gilead, Sanofi, AbbVie and generic manufacturers |
AstraZeneca’s commercial model is less dependent on a single therapeutic category than companies focused on one platform, but its oncology business remains central to valuation. Tagrisso is the largest individual product franchise, while Farxiga and Ultomiris provide important non-oncology growth.
The company has also increased its exposure to antibody-drug conjugates through its partnership with Daiichi Sankyo. Enhertu is marketed jointly with Daiichi Sankyo and competes directly with Roche’s Kadcyla and Trodelvy from Gilead in several breast and solid-tumor settings.
How much revenue does AstraZeneca generate from its leading medicines?
AstraZeneca’s revenue base is concentrated in a group of products with strong clinical differentiation and broad geographic approval.
| Product |
Active ingredient or platform |
Primary markets |
Competitive position |
| Tagrisso |
Osimertinib |
EGFR-mutated non-small-cell lung cancer |
Leading targeted EGFR therapy |
| Farxiga |
Dapagliflozin |
Diabetes, heart failure and chronic kidney disease |
Major SGLT2 inhibitor |
| Imfinzi |
Durvalumab |
Lung, liver, biliary and other cancers |
Broad checkpoint-inhibitor franchise |
| Calquence |
Acalabrutinib |
Chronic lymphocytic leukemia and related B-cell malignancies |
Competes with Imbruvica and Brukinsa |
| Ultomiris |
Ravulizumab |
Complement-mediated rare diseases |
Long-acting successor to Soliris |
| Fasenra |
Benralizumab |
Severe eosinophilic asthma |
Competes with Dupixent, Nucala and Tezspire |
| Symbicort |
Budesonide/formoterol |
Asthma and COPD |
Mature respiratory franchise exposed to generics |
| Lynparza |
Olaparib |
Oncology |
PARP inhibitor marketed with Merck |
| Enhertu |
Trastuzumab deruxtecan |
HER2-positive and HER2-low cancers |
High-growth antibody-drug conjugate |
Product sales rankings change by reporting period, exchange rates, and treatment indication. Tagrisso, Farxiga, Imfinzi, Calquence, Ultomiris and Fasenra are among the company’s most important commercial assets. The company’s collaboration economics also matter: AstraZeneca does not retain all reported value from jointly developed products such as Enhertu and Lynparza.
What patents protect AstraZeneca’s major drugs?
AstraZeneca’s patent protection is product-specific and jurisdiction-specific. The company relies on compound patents, formulation patents, crystalline-form patents, dosing patents, combination-treatment patents, manufacturing patents and method-of-use patents. The effective loss-of-exclusivity date often differs from the basic compound-patent expiry because of patent-term extensions, pediatric extensions, regulatory exclusivity and settlement agreements.
Selected patent and exclusivity profile
| Product |
Main patent-risk issue |
Expected timing of major generic or biosimilar risk |
| Tagrisso |
Osimertinib compound, formulation and method-of-use claims |
Late 2020s to early 2030s, depending on jurisdiction and patent claims |
| Farxiga |
Dapagliflozin compound and formulation patents |
United States generic risk in the early 2030s, subject to litigation and patent outcomes |
| Symbicort |
Inhaled formulation and device-related protection |
Generic competition has already begun in the United States |
| Fasenra |
Biologic composition, formulation and use patents |
Biosimilar risk is later and depends on interchangeability and patent resolution |
| Ultomiris |
Biologic composition, dosing, formulation and method-of-use patents |
Biosimilar risk is likely later than small-molecule generic risk |
| Imfinzi |
Durvalumab biologic and oncology-use patents |
Biosimilar risk depends on patent expiry and regulatory development |
| Calquence |
Acalabrutinib compound, formulation and use patents |
Generic risk expected after key U.S. patent protection expires, subject to litigation |
| Lynparza |
Olaparib compound and use patents |
Generic entry risk is moderated by collaboration and use-specific patent coverage |
The Orange Book identifies patents and regulatory exclusivities for eligible small-molecule products. Biologic products such as Imfinzi, Fasenra and Ultomiris are generally protected through the Biologics Price Competition and Innovation Act framework and are not listed in the Orange Book in the same way as conventional small-molecule drugs. FDA’s Purple Book is the central reference for biologic licensure and biosimilar information (U.S. Food and Drug Administration, 2025a, 2025b).
Patent dates should be checked against current Orange Book entries, FDA approval supplements, patent-term-extension records and litigation dockets before use in a launch or investment decision.
When does AstraZeneca lose exclusivity on its major products?
AstraZeneca has a staggered exclusivity profile rather than one concentrated patent cliff.
Tagrisso exclusivity
Tagrisso is protected by a combination of osimertinib compound, formulation and treatment patents. The core commercial risk is generic osimertinib after expiry of the strongest enforceable U.S. claims. AstraZeneca has expanded Tagrisso into adjuvant and unresectable stage III settings, increasing the importance of method-of-use patents and regulatory exclusivity.
Tagrisso competes with other EGFR therapies, including Janssen’s Rybrevant and lazertinib combinations, Roche’s Tarceva legacy franchise, and generic first-generation EGFR inhibitors. The principal competitive threat is clinical displacement before generic entry, not only post-expiry price erosion.
Farxiga exclusivity
Farxiga competes with Eli Lilly and Boehringer Ingelheim’s Jardiance and Merck’s Steglatro. Its growth in heart failure and chronic kidney disease has reduced dependence on type 2 diabetes use. The franchise is protected by compound and use claims, but the market is exposed to U.S. Paragraph IV litigation and eventual generic dapagliflozin.
The commercial impact of generic entry could be substantial because Farxiga is a high-volume chronic therapy with broad primary-care and cardiology use.
Symbicort exclusivity
Symbicort has entered the mature-product phase. The product’s inhaled corticosteroid and long-acting beta-agonist combination is exposed to generic competition, but device engineering, inhaler equivalence, manufacturing capability and regulatory requirements create barriers beyond a conventional oral generic.
The U.S. market has seen authorized and third-party generic activity. AstraZeneca’s defense has shifted from compound exclusivity toward device, formulation, supply and franchise retention.
Ultomiris and Soliris
Ultomiris is a long-acting successor to Soliris. The products inhibit complement component 5, but Ultomiris requires distinct biologic manufacturing, formulation and dosing protection. AstraZeneca uses conversion from Soliris to Ultomiris to extend the commercial life of the complement franchise.
The main future risk is biosimilar or follow-on competition. Entry requires a sufficiently similar biologic, regulatory approval, manufacturing capacity and resolution of patent disputes. Physician familiarity, hospital procurement and rare-disease treatment networks also affect switching.
Which companies compete most directly with AstraZeneca?
AstraZeneca faces different competitors by therapeutic area.
Oncology competitors
Merck is the most important competitor in checkpoint inhibition through Keytruda. Bristol Myers Squibb competes through Opdivo, Yervoy and oncology combinations. Roche competes in HER2, lung and hematologic cancers. Johnson & Johnson, Novartis, Pfizer, Gilead and AbbVie compete across targeted therapies, cell therapy, antibody-drug conjugates and hematology.
AstraZeneca’s oncology advantage is portfolio breadth. Its primary weakness is the high cost of maintaining clinical leadership across multiple tumor types and biomarker-defined populations.
Cardiovascular, renal and metabolic competitors
Farxiga competes directly with Jardiance. Novo Nordisk and Eli Lilly dominate obesity and diabetes innovation through GLP-1 therapies, creating a strategic challenge for AstraZeneca’s metabolic ambitions. AstraZeneca’s strongest position is in cardiorenal disease, where dapagliflozin has indications beyond glycemic control.
Respiratory competitors
Dupixent from Sanofi and Regeneron is the principal competitive threat in severe asthma and type 2 inflammatory disease. GSK’s Nucala, Amgen’s Tezspire and AstraZeneca’s Fasenra compete for biologic-treated asthma patients. In COPD and inhaled maintenance therapy, AstraZeneca competes with GSK, Boehringer Ingelheim, Novartis and generic manufacturers.
Rare-disease competitors
Alexion’s complement platform competes with Roche’s Piasky and other complement inhibitors, as well as emerging therapies from Novartis, Regeneron, Apellis and specialized biotechnology companies. The competitive basis includes durability of response, dosing frequency, route of administration, vaccination and infection-management requirements, and total treatment cost.
How strong is AstraZeneca’s patent estate?
AstraZeneca’s patent estate is strong in aggregate, but strength varies materially by product.
Strongest patent characteristics
- Complex biologic manufacturing. Monoclonal antibodies and antibody-drug conjugates are difficult to reproduce at commercial scale.
- Multiple indications. Oncology labels create separate method-of-use opportunities tied to biomarkers, disease stages and treatment combinations.
- Lifecycle management. The company has converted Soliris to Ultomiris and expanded mature products into new settings.
- Combination patents. Products such as Lynparza and Imfinzi benefit from combination-treatment development.
- Device and formulation protection. Inhaled products have additional technical barriers that do not apply to tablets.
Principal weaknesses
- High-value small molecules eventually face abbreviated new drug applications.
- Method-of-use patents can be vulnerable to validity and infringement challenges.
- Broad patent portfolios create litigation expense but do not guarantee market exclusivity.
- Patent settlements can delay entry without eliminating long-term erosion.
- Biologic protection is exposed to biosimilar development after regulatory and patent barriers decline.
Patent strength should be assessed claim by claim. A large number of listed patents does not establish equivalent commercial value. Compound patents generally provide stronger protection than narrow dosing or formulation patents, while biologic estates depend heavily on manufacturing and clinical-use claims.
What Paragraph IV challenges and patent litigation affect AstraZeneca?
Paragraph IV challenges are most relevant to AstraZeneca’s small-molecule products. A generic applicant may certify that an Orange Book-listed patent is invalid, unenforceable or not infringed. AstraZeneca can sue within the statutory period, triggering a regulatory stay that can delay FDA approval for a limited period under the Hatch-Waxman framework.
Key litigation exposure has historically involved mature and high-revenue products such as Farxiga, Symbicort and other small-molecule medicines. Litigation outcomes can produce three commercial scenarios:
| Scenario |
Market consequence |
| AstraZeneca prevails on key patents |
Generic launch is delayed until later patent expiry |
| Generic company prevails |
Early launch may occur, subject to court order and remaining claims |
| Settlement permits later entry |
Entry date is fixed contractually, often with confidential commercial terms |
Biologic products follow a different pathway. Biosimilar applicants exchange patent information under the BPCIA, and litigation may involve composition, formulation, manufacturing and use patents. The timing of biosimilar launch depends on FDA approval, patent litigation, settlement terms and commercial readiness.
What is the FDA and Orange Book status of AstraZeneca products?
Small-molecule AstraZeneca products approved through the NDA pathway may have Orange Book listings. These commonly include Tagrisso, Farxiga, Calquence, Lynparza and Symbicort. The Orange Book lists approved products, patent information and regulatory exclusivity where applicable (U.S. Food and Drug Administration, 2025a).
Biologics including Imfinzi, Fasenra and Ultomiris are tracked primarily through FDA biologics records and the Purple Book. The Purple Book identifies licensed biologics and biosimilar relationships, including interchangeability status where applicable (U.S. Food and Drug Administration, 2025b).
FDA approval does not eliminate patent risk. A product can have approval while an ANDA or biosimilar applicant remains blocked from commercial launch by enforceable patents or an agreed settlement date.
What licensing deals and acquisitions strengthen AstraZeneca?
AstraZeneca has used acquisitions and licensing to build its current portfolio.
| Transaction or relationship |
Strategic impact |
| Alexion acquisition |
Added complement biology, rare-disease infrastructure and Ultomiris/Soliris |
| Daiichi Sankyo collaboration |
Added Enhertu and expanded antibody-drug-conjugate capabilities |
| Merck collaboration |
Supported Lynparza development and commercialization |
| Amgen collaboration |
Supports Tezspire commercialization in severe asthma |
| Gracell acquisition |
Expanded cell-therapy capabilities and oncology pipeline |
| Fusion Pharmaceuticals acquisition |
Added targeted alpha therapy technology |
The Daiichi Sankyo relationship is strategically important because antibody-drug conjugates can generate multiple products from a shared technical platform. The Alexion acquisition diversified AstraZeneca away from traditional primary-care and oncology economics, but it also increased exposure to high-cost rare-disease therapies and reimbursement scrutiny.
What generic entry risks exist for AstraZeneca?
Generic-entry risk is highest for high-volume oral medicines with clear active ingredients and established manufacturing processes. Farxiga and Calquence represent larger long-term risks than biologic products because ANDA pathways are generally more direct than biosimilar development.
Generic launch scenarios
- Immediate launch after patent invalidation or non-infringement.
- Delayed launch after a negotiated settlement.
- Authorized generic or branded price defense.
- Limited indication launch based on skinny-label strategy.
- Sequential entry by several generic manufacturers after the first launch.
For Symbicort, device and inhalation-equivalence requirements can slow competition but do not remove it. For oral oncology medicines, generic price erosion can be severe because payers rapidly substitute once multiple suppliers enter.
What biosimilar risks affect AstraZeneca?
AstraZeneca’s biosimilar risk is concentrated in biologic products and is structurally later than small-molecule generic risk. The most relevant assets include Ultomiris, Soliris, Imfinzi and Fasenra.
Biosimilar competition depends on:
- Patent expiry and litigation outcomes.
- Availability of a commercially scalable manufacturing process.
- FDA approval and, where relevant, interchangeability designation.
- Payer incentives and formulary placement.
- Physician willingness to switch stable patients.
- The complexity of rare-disease monitoring and treatment centers.
A biosimilar to a rare-disease biologic may enter slowly because the patient population is small and treatment logistics are specialized. A biosimilar to a widely used oncology antibody can face stronger payer pressure but requires substantial clinical and manufacturing investment.
How does AstraZeneca compare with Merck, Roche and Bristol Myers Squibb?
| Company |
Principal strength |
Relative AstraZeneca advantage |
Relative AstraZeneca weakness |
| AstraZeneca |
Oncology, rare disease, cardiorenal medicine |
Broad growth portfolio and strong late-stage pipeline |
Heavy reliance on a few blockbuster franchises |
| Merck |
Keytruda and vaccines |
More diversified oncology mechanisms |
Less exposure to rare disease than AstraZeneca |
| Roche |
Oncology diagnostics and biologics |
Stronger cardiorenal and complement position |
Roche has deeper diagnostic integration |
| Bristol Myers Squibb |
Hematology, immuno-oncology and cardiovascular disease |
Stronger respiratory and rare-disease breadth |
BMS has major exposure to near-term Eliquis/Opdivo patent issues |
| GSK |
Respiratory and vaccines |
Stronger oncology and rare disease |
GSK has greater vaccine scale |
| Novartis |
Cardiovascular, immunology and radioligand therapy |
Broader respiratory and antibody portfolio |
Novartis has strong radioligand and specialty-cardiovascular positioning |
AstraZeneca’s portfolio is competitively strongest where it combines a validated mechanism with multiple indications, such as Tagrisso in EGFR-mutated lung cancer, Farxiga in cardiorenal disease and Ultomiris in complement-mediated disorders.
What manufacturing and intellectual-property barriers protect AstraZeneca?
AstraZeneca’s manufacturing barriers are most significant for antibody-drug conjugates, monoclonal antibodies, inhaled products and cell therapies.
Manufacturing protection can arise from:
- Antibody and linker-payload production.
- Drug-to-antibody ratio control in antibody-drug conjugates.
- Cell-line development and biologic purification.
- Sterile fill-finish capacity.
- Inhaler-device engineering.
- Specialized quality-control assays.
- Cold-chain and distribution requirements.
These barriers do not replace patents. They can delay competition, increase development costs and reduce the number of credible entrants. They are particularly relevant to Enhertu, Ultomiris, Imfinzi and Fasenra.
What is AstraZeneca’s strategic outlook?
AstraZeneca’s strategy is centered on replacing mature-product erosion through oncology expansion, rare-disease growth, cardiorenal indications and platform acquisitions. The company has a strong position if new indications convert existing scientific assets into larger addressable markets.
The main execution tests are:
- Sustaining Tagrisso growth despite EGFR competition and eventual generic entry.
- Expanding Farxiga beyond diabetes while defending against Jardiance.
- Converting antibody-drug-conjugate research into additional commercial products.
- Managing the cost and complexity of rare-disease manufacturing.
- Replacing revenue from Symbicort and other mature medicines.
- Defending patents without allowing litigation costs and settlements to reduce returns.
- Maintaining regulatory and commercial momentum in China and other major markets.
Key Takeaways
- AstraZeneca is a global specialty pharmaceutical leader with approximately $54.1 billion in 2024 revenue.
- Oncology is the company’s largest commercial engine, led by Tagrisso, Imfinzi, Calquence, Lynparza and Enhertu-related economics.
- Farxiga provides major cardiorenal growth but faces direct competition from Jardiance and eventual generic dapagliflozin.
- Ultomiris and Alexion give AstraZeneca a strong rare-disease platform with later-cycle biosimilar risk.
- The patent estate is broad, but commercial protection varies by product, claim type and jurisdiction.
- Symbicort is already exposed to generic competition, while Tagrisso, Farxiga and Calquence represent important future small-molecule exclusivity risks.
- Biologic and manufacturing barriers materially strengthen protection for Ultomiris, Imfinzi, Fasenra and antibody-drug conjugates.
- AstraZeneca’s strategic success depends on pipeline productivity, lifecycle management and disciplined defense of high-value patents.
FAQs About AstraZeneca’s Competitive and Patent Position
Which AstraZeneca drug faces the largest future generic risk?
Farxiga is one of the most important future generic-risk assets because it has broad chronic use across diabetes, heart failure and chronic kidney disease. Calquence and Tagrisso are also significant risks after their strongest enforceable patents expire.
Does AstraZeneca have biosimilar competition?
AstraZeneca’s biologics, including Ultomiris, Soliris, Imfinzi and Fasenra, may face biosimilar competition after regulatory and patent barriers decline. The timing depends on FDA approval, patent litigation and commercial manufacturing capability.
Is Tagrisso protected by method-of-use patents?
Yes. Tagrisso protection includes product-related claims and treatment-use claims covering specific EGFR-mutated cancers, treatment settings and dosing approaches. The commercial value of each claim depends on enforceability and the approved label.
Which company is AstraZeneca’s strongest oncology competitor?
Merck is the broadest oncology competitor through Keytruda. Roche, Bristol Myers Squibb, Johnson & Johnson, Novartis, Pfizer and Gilead are also significant competitors in targeted therapy, immuno-oncology, hematology and antibody-drug conjugates.
Does the Orange Book show all AstraZeneca patent protection?
No. The Orange Book primarily covers eligible small-molecule products and listed patents. Biologic protection is addressed through FDA biologics records, the Purple Book, patent litigation and BPCIA procedures.
References
AstraZeneca. (2025a). Annual report and Form 20-F 2024. https://www.astrazeneca.com/investor-relations/annual-reports.html
AstraZeneca. (2025b). Product sales and pipeline information. https://www.astrazeneca.com/our-company.html
U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2025b). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
U.S. Food and Drug Administration. (2025c). Abbreviated new drug application and Paragraph IV certification resources. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda
U.S. Food and Drug Administration. (2025d). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information-
